{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:39:20Z","timestamp":1783564760070,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T00:00:00Z","timestamp":1413158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2431-14-261","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T03:01:04Z","timestamp":1413169264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Leonard R","family":"Krilov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S","family":"Masaquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally W","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthiv J","family":"Mahadevia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,13]]},"reference":[{"issue":"15","key":"1220_CR1","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1001\/jama.282.15.1440","volume":"282","author":"DK Shay","year":"1999","unstructured":"Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ: Bronchiolitis-associated hospitalizations among US children, 1980\u20131996. JAMA. 1999, 282 (15): 1440-1446. 10.1001\/jama.282.15.1440.","journal-title":"JAMA"},{"issue":"1","key":"1220_CR2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.18553\/jmcp.2010.16.1.46","volume":"16","author":"MP Frogel","year":"2010","unstructured":"Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ: A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010, 16 (1): 46-58.","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"1220_CR3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.18553\/jmcp.2010.16.1.23","volume":"16","author":"JL Diehl","year":"2010","unstructured":"Diehl JL, Daw JR, Coley KC, Rayburg R: Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan. J Manag Care Pharm. 2010, 16 (1): 23-31.","journal-title":"J Manag Care Pharm"},{"issue":"5","key":"1220_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00019053-200422050-00001","volume":"22","author":"LC Paramore","year":"2004","unstructured":"Paramore LC, Ciuryla V, Ciesla G, Liu L: Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics. 2004, 22 (5): 275-284. 10.2165\/00019053-200422050-00001.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1220_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1067\/mpd.2000.110531","volume":"137","author":"TG Boyce","year":"2000","unstructured":"Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR: Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000, 137 (6): 865-870. 10.1067\/mpd.2000.110531.","journal-title":"J Pediatr"},{"issue":"7","key":"1220_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/jp.2008.28","volume":"28","author":"M Frogel","year":"2008","unstructured":"Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M: Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008, 28 (7): 511-517. 10.1038\/jp.2008.28.","journal-title":"J Perinatol"},{"issue":"3","key":"1220_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jpeds.2006.04.063","volume":"149","author":"L Sangare","year":"2006","unstructured":"Sangare L, Curtis MP, Ahmad S: Hospitalization for respiratory syncytial virus among California infants: disparities related to race, insurance, and geography. J Pediatr. 2006, 149 (3): 373-377. 10.1016\/j.jpeds.2006.04.063.","journal-title":"J Pediatr"},{"issue":"3 Pt 1","key":"1220_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1542\/peds.102.3.531","volume":"102","author":"The Impact RSV Study Group","year":"1998","unstructured":"The Impact RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. the IMpact-RSV Study Group. Pediatrics. 1998, 102 (3 Pt 1): 531-537.","journal-title":"Pediatrics"},{"issue":"4","key":"1220_CR9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","volume":"143","author":"TF Feltes","year":"2003","unstructured":"Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003, 143 (4): 532-540. 10.1067\/S0022-3476(03)00454-2.","journal-title":"J Pediatr"},{"issue":"6","key":"1220_CR10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jpeds.2009.12.016","volume":"156","author":"C Hampp","year":"2010","unstructured":"Hampp C, Saidi AS, Winterstein AG: Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J Pediatr. 2010, 156 (6): 953-959. 10.1016\/j.jpeds.2009.12.016. 959 e951","journal-title":"J Pediatr"},{"key":"1220_CR11","unstructured":"Respiratory Syncytial Virus (RSV) Season, U.S. 2010\u20132011. http:\/\/www.cdc.gov\/rsv\/research\/us-surveillance.html . Accessed November 11, 2011."},{"key":"1220_CR12","unstructured":"Highlights of Synagis (palivizumab) prescribing information. http:\/\/www.medimmune.com\/pdf\/products\/synagis_pi.pdf . Accessed November 11, 2011."},{"key":"1220_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1164\/rccm.168.3.356","volume":"168","author":"American Thoracic Society","year":"2003","unstructured":"American Thoracic Society: Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med. 2003, 168: 356-396.","journal-title":"Am J Respir Crit Care Med"},{"key":"1220_CR14","unstructured":"Centers for Medicare and Medicaid Services. National summary of medicaid managed care programs and enrollment as of July 1, 2010. https:\/www.cms.gov\/MedicaidDataSourcesGenInfo\/06_DescStateProg.asp . Accessed November 11, 2011."},{"issue":"1","key":"1220_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/pds.2246","volume":"21","author":"AG Winterstein","year":"2012","unstructured":"Winterstein AG, Hampp C, Saidi A: Effectiveness of palivizumab prophylaxis in infants and children in Florida. Pharmacoepidemiol Drug Saf. 2012, 21 (1): 53-60. 10.1002\/pds.2246.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1220_CR16","volume-title":"29th Annual Meeting of the European Society for Paediatric Infectious Diseases","author":"K Gooch","year":"2011","unstructured":"Gooch K, Busch K, Khong H: Length of hospital stay for respiratory syncytial virus in prophylaxed versus non-prophylaxed infants. 29th Annual Meeting of the European Society for Paediatric Infectious Diseases. 2011, The Hague, The Netherlands"},{"key":"1220_CR17","volume-title":"Red Book: 2009 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2009","unstructured":"American Academy of Pediatrics: Respiratory Syncytial Virus. Red Book: 2009 Report of the Committee on Infectious Diseases. Edited by: Pickering LK BC, Kimberlin DW, Long SS. 2009, Elk Grove Village, IL: American Academy of Pediatrics, 28","edition":"28"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2431-14-261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2431-14-261\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2431-14-261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T20:58:06Z","timestamp":1650401886000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/1471-2431-14-261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,13]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1186\/1471-2431-14-261","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,13]]},"article-number":"261"}}